Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tuoyi

(Camrelizumab)

Phase 3Monoclonal antibody

SSun Yat-sen University

Camrelizumab is used to treat certain types of cancer, including lung cancer and lymphoma, by helping the immune system recognize and attack cancer cells.[1] Tuoyi is currently being investigated across 70 indications[3], with its most advanced program in Phase 3.[1]

Tuoyi is one of 1174 small molecule programs targeting Pancreatic Carcinoma. It is currently in Phase 3.

70

Indications

225

Total Trials

83

Active Trials

1,173

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Gestational Trophoblastic NeoplasmActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal CarcinomaActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Hypopharyngeal CarcinomaActive, not recruiting

Oral Squamous Cell CarcinomaActive, not recruiting

Pancreatic CarcinomaPhase 2

Active, not recruiting

Gestational Trophoblastic NeoplasmPhase 2

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Esophageal CarcinomaPhase 3

Active, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Hypopharyngeal CarcinomaPhase 2

Active, not recruiting

Oral Squamous Cell CarcinomaPhase 2

Active, not recruiting

Showing 10 of 70 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tuoyi

SSun Yat-sen University

Halaven

Trodelvy

Tykerb

Tecentriq

Adriamycin

GGynecologic Oncology Group

Avastin

BBio-Thera Solutions

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Prolia

Gemzar

GGynecologic Oncology Group

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Hepatocellular Carcinoma

NCT04639180

Phase 2Recruiting

Stereotactic Body Radiotherapy

NCT04830267

Phase 3Recruiting

Efficacy and Safety

NCT04342910

Phase 2Not yet recruiting

Hepatocellular Carcinoma

NCT06546280

Q4 2026

Phase 1/2Recruiting

Efficacy and Safety

NCT04481763

Gastric Cancer

NCT06485271

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma19 trials

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Completed·NNanfang Hospital, Southern Medical University·Phase 2·NCT05003700·39 enrolled

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Not yet recruiting·FFudan University··NCT07147101·150 enrolled

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Unknown status·YYue Han·Phase 2·NCT05135364·48 enrolled

Show 16 more trials

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04639180·687 enrolled

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Recruiting·SSun Yat-sen University··NCT06333561·300 enrolled

Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT04479527·34 enrolled

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Recruiting·SSun Yat-sen University··NCT06323382·240 enrolled

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT05367687·251 enrolled

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT05613478·130 enrolled

A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2/3·NCT07309419·222 enrolled

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT05099848·21 enrolled

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting·FFujian Medical University·Phase 2·NCT06363825·57 enrolled

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital··NCT04947956·1,000 enrolled

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Unknown status·—·Phase 2·NCT04850040·15 enrolled

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Not yet recruiting·ZZhujiang Hospital·Phase 2·NCT06546280·38 enrolled

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Active, not recruiting·SShanghai Zhongshan Hospital·Phase 2/3·NCT04521153·294 enrolled

Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

Recruiting·FFudan University·Phase 2·NCT07100392·141 enrolled

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Completed·SSun Yat-sen University··NCT04627012·600 enrolled

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma

Unknown status·ZZhejiang University·Phase 2·NCT04930315·78 enrolled

Gastric Cancer18 trials

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Active, not recruiting·RRuijin Hospital·Phase 2/3·NCT04208347·580 enrolled

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Unknown status·RRenJi Hospital·Phase 2·NCT04152889·20 enrolled

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT05342389·68 enrolled

Show 15 more trials

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 1/2·NCT04572542·46 enrolled

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Recruiting·SShandong Tumor Hospital·Phase 2·NCT07320586·40 enrolled

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05669807·184 enrolled

Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

Active, not recruiting·YYu jiren·Phase 2·NCT04515615·52 enrolled

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Unknown status·ZZhou Fuxiang·Phase 2·NCT04781686·35 enrolled

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Active, not recruiting·RRuijin Hospital·Phase 2·NCT06693128·80 enrolled

Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer

Unknown status·—·Phase 2·NCT04367025·70 enrolled

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Not yet recruiting·FFujian Medical University·Phase 2·NCT05524974·203 enrolled

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Completed·FFujian Medical University·Phase 2·NCT04195828·106 enrolled

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Recruiting·—··NCT06485271·504 enrolled

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Unknown status·FFujian Cancer Hospital·N/A·NCT04174339·20 enrolled

Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

Not yet recruiting·FFujian Medical University·Phase 3·NCT05610332·216 enrolled

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

Active, not recruiting·TThe Second Affiliated Hospital of Fujian Medical University·Phase 2·NCT05602935·29 enrolled

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Completed·QQuan Wang·Phase 2·NCT04694183·37 enrolled

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Unknown status·FFudan University·Phase 2·NCT05095636·102 enrolled

Camrelizumab10 trials

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Unknown status·HHuiqiang Huang·Phase 1/2·NCT04476459·33 enrolled

Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL

Unknown status·SSun Yat-sen University·Phase 2·NCT05093140·30 enrolled

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04303741·46 enrolled

Show 7 more trials

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Recruiting·QQian Chu·Phase 2·NCT04888429·28 enrolled

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Unknown status·HHenan Cancer Hospital·Phase 2·NCT06231680·132 enrolled

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Unknown status·SSun Yat-sen University·Phase 2·NCT04454905·50 enrolled

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Unknown status·ZZhongda Hospital·N/A·NCT04559607·188 enrolled

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT04683198·69 enrolled

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT05171309·35 enrolled

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

Completed·PPeking Union Medical College Hospital·Phase 2·NCT04047017·20 enrolled

Nasopharyngeal Carcinoma10 trials

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Recruiting·FFudan University·Phase 3·NCT05772208·459 enrolled

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03707509·263 enrolled

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT04221516·52 enrolled

Show 7 more trials

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04547088·27 enrolled

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Recruiting·EEye & ENT Hospital of Fudan University·Phase 2·NCT05011227·100 enrolled

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Recruiting·WWei Jiang·Phase 2·NCT05097209·200 enrolled

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT05524168·41 enrolled

Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

Unknown status·SShanghai Proton and Heavy Ion Center·Phase 2·NCT04143984·146 enrolled

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT04944914·188 enrolled

PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT03427827·450 enrolled

Breast Cancer10 trials

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT06121557·24 enrolled

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05981001·170 enrolled

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04805736·60 enrolled

Show 7 more trials

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Unknown status·AAiping Shi·Phase 2·NCT05088057·30 enrolled

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Recruiting·FFudan University·Phase 2·NCT06516289·130 enrolled

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2/3·NCT04907344·420 enrolled

A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT06530082·48 enrolled

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT04676997·20 enrolled

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Recruiting·WWest China Hospital·Phase 2·NCT05447702·35 enrolled

64 more indications

Esophageal Cancer8 trials

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Recruiting·FFujian Cancer Hospital·Phase 2·NCT05624099·75 enrolled

A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

Not yet recruiting·PPeking University··NCT04616040·1,030 enrolled

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03099382·457 enrolled

Show 5 more trials

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05183958·118 enrolled

A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04512417·63 enrolled

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

Unknown status·XXijing Hospital·N/A·NCT05050760·55 enrolled

Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer

Unknown status·TThe First Affiliated Hospital of Henan University of Science and Technology·Phase 2·NCT04390945·62 enrolled

Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04426955·396 enrolled

Non-Small Cell Lung Cancer7 trials

Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer

Unknown status·HHenan Cancer Hospital··NCT05547737·500 enrolled

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT05042375·450 enrolled

Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04828395·65 enrolled

Show 4 more trials

A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer

Completed·—··NCT05387512·59 enrolled

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Active, not recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04379739·89 enrolled

Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT05472467·35 enrolled

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy

Unknown status·WWuhan University·Phase 2·NCT04878107·88 enrolled

Esophageal Squamous Cell Carcinoma7 trials

Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Unknown status·FFuzhou General Hospital·N/A·NCT04741490·20 enrolled

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05637268·23 enrolled

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 1/2·NCT04506138·46 enrolled

Show 4 more trials

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

Not yet recruiting·WWest China Hospital·Phase 2·NCT07191977·41 enrolled

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

Recruiting·WWest China Hospital·Phase 1·NCT06654297·6 enrolled

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Completed·GGuangzhou Institute of Respiratory Disease·Phase 2·NCT04225364·56 enrolled

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

Enrolling by invitation·PPeking University·Phase 2·NCT07312578·48 enrolled

Lymphoma6 trials

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Recruiting·—·Phase 1/2·NCT04337606·100 enrolled

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

Unknown status·HHuazhong University of Science and Technology·Phase 2·NCT05320081·30 enrolled

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Recruiting·—·Phase 1/2·NCT06376721·43 enrolled

Show 3 more trials

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Unknown status·—·Phase 2·NCT04233294·100 enrolled

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Active, not recruiting·HHenan Cancer Hospital·Phase 2·NCT04067037·60 enrolled

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04342936·56 enrolled

Cervical Cancer6 trials

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04974944·172 enrolled

A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

Not yet recruiting·JJin LI·N/A·NCT07466901·30 enrolled

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Unknown status·HHunan Cancer Hospital·Phase 2·NCT04974827·46 enrolled

Show 3 more trials

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer

Not yet recruiting·QQi Zhou··NCT07266350·1,300 enrolled

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Recruiting·TTongji Hospital·Phase 2·NCT06289062·40 enrolled

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04884906·40 enrolled

First-line Treatment6 trials

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Recruiting·FFudan University·Phase 3·NCT05760378·223 enrolled

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Recruiting·SSun Yat-sen University·Phase 3·NCT05854849·244 enrolled

First-line Treatment of Advanced/unresectable DDLPS

Not yet recruiting·FFudan University·Phase 2·NCT06694324·49 enrolled

Show 3 more trials

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Completed·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT05156970·81 enrolled

Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT04303130·52 enrolled

PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

Unknown status·SSun Yat-sen University·Phase 2·NCT05222035·68 enrolled

Colorectal Cancer5 trials

A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis

Unknown status·HHarbin Medical University·Phase 2·NCT04888806·37 enrolled

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 1/2·NCT04202978·23 enrolled

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 1/2·NCT04067986·62 enrolled

Show 2 more trials

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Unknown status·FFudan University·Phase 2·NCT05193292·77 enrolled

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Unknown status·PPeking Union Medical College Hospital··NCT04771715·100 enrolled

Triple-Negative Breast Cancer5 trials

Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer

Not yet recruiting·—·Phase 2·NCT07107217·40 enrolled

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Active, not recruiting·HHarbin Medical University·Phase 2·NCT07471815·30 enrolled

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Not yet recruiting·HHarbin Medical University·Phase 1/2·NCT07161791·12 enrolled

Show 2 more trials

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Unknown status·FFudan University·Phase 2·NCT05438706·70 enrolled

HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06849492·120 enrolled

Head and Neck Squamous Cell Carcinoma4 trials

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

Recruiting·WWest China Hospital·Phase 1·NCT06109207·6 enrolled

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04440917·32 enrolled

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Unknown status·—·Phase 2·NCT06170697·46 enrolled

Show 1 more trial

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT04861467·155 enrolled

Pancreatic Cancer4 trials

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Recruiting·RRenJi Hospital·Phase 3·NCT04674956·401 enrolled

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Recruiting·JJinling Hospital, China·Phase 1·NCT06326736·12 enrolled

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06196671·30 enrolled

Show 1 more trial

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT04498689·117 enrolled

Efficacy and Safety4 trials

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Recruiting·JJiangxi Provincial Cancer Hospital·Phase 1/2·NCT04481763·20 enrolled

Efficacy and Safety of Camrelizumab in Real-World Study

Unknown status·GGuangdong Association of Clinical Trials··NCT04631146·450 enrolled

Efficacy and Safety of Camrelizumab in Real-World Prospective Study

Unknown status·GGuangdong Association of Clinical Trials··NCT04793139·1,000 enrolled

Show 1 more trial

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04342910·550 enrolled

Melanoma4 trials

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Recruiting·PPeking University Cancer Hospital & Institute·Phase 3·NCT05789043·140 enrolled

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT05512481·60 enrolled

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT05051865·60 enrolled

Show 1 more trial

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

Unknown status·DDi Wu·Phase 2·NCT04979585·66 enrolled

Metastatic Colorectal Cancer3 trials

Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Recruiting·Yyue junhan·Phase 2·NCT06176885·36 enrolled

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Unknown status·WWest China Hospital·Phase 1·NCT05019534·12 enrolled

Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT03912857·50 enrolled

Concurrent Chemoradiotherapy2 trials

A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC

Unknown status·HHebei Medical University Fourth Hospital·Phase 2·NCT04286958·40 enrolled

A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

Unknown status·HHunan Cancer Hospital·Phase 2·NCT05151549·46 enrolled

Neoadjuvant Chemotherapy2 trials

Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell

Unknown status·FFudan University·Phase 2·NCT04520035·60 enrolled

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Recruiting·ZZhigang Li·Phase 3·NCT05043688·426 enrolled

Biliary Tract Cancer2 trials

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07159217·65 enrolled

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Completed·—·Phase 2·NCT04720131·28 enrolled

Brain Metastases2 trials

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Unknown status·GGuangdong Association of Clinical Trials·Phase 3·NCT04768075·200 enrolled

Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC

Unknown status·SSun Yat-sen University·Phase 2·NCT04211090·45 enrolled

Endometrial Cancer2 trials

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Recruiting·WWomen's Hospital School Of Medicine Zhejiang University·Phase 2·NCT06561308·39 enrolled

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Recruiting·—·Phase 2·NCT06413992·117 enrolled

Soft Tissue Sarcoma2 trials

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Unknown status·HHenan Cancer Hospital·Phase 2·NCT05189483·40 enrolled

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT04910126·84 enrolled

Locally-advanced Rectal Cancer2 trials

Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1/2·NCT04231552·30 enrolled

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT07057089·90 enrolled

Esophageal Carcinoma2 trials

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Not yet recruiting·FFujian Medical University Union Hospital·Phase 2·NCT05821452·40 enrolled

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Active, not recruiting·FFujian Medical University Union Hospital·Phase 1/2·NCT05176002·25 enrolled

Intrahepatic Cholangiocarcinoma2 trials

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

Recruiting·FFudan University·Phase 2·NCT04299581·25 enrolled

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Unknown status·HHua Li·Phase 2·NCT05738057·22 enrolled

Neoadjuvant Chemoimmunotherapy2 trials

Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC

Not yet recruiting·NNational Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT07400094·50 enrolled

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Recruiting·TTongji Hospital·Phase 2/3·NCT06288373·440 enrolled

Adenocarcinoma2 trials

A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab

Unknown status·HHenan Cancer Hospital·N/A·NCT05583383·62 enrolled

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Unknown status·FFudan University·Phase 2·NCT05111444·65 enrolled

Treatment2 trials

Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04126993·80 enrolled

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Not yet recruiting·PPeking University Shenzhen Hospital·Phase 2·NCT06692491·200 enrolled

Oral Squamous Cell Carcinoma2 trials

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Completed·SShanghai Jiao Tong University School of Medicine·Phase 1·NCT04393506·21 enrolled

Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma

Completed·HHospital of Stomatology, Wuhan University·Phase 2·NCT04649476·68 enrolled

Nab-paclitaxel1 trial

A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06632405·60 enrolled

Ovarian Clear Cell Carcinoma1 trial

A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma

Unknown status·PPeking University Third Hospital·N/A·NCT05600998·20 enrolled

Adrenal Cortical Carcinoma1 trial

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Recruiting·WWest China Hospital·Phase 2·NCT06831175·28 enrolled

Stereotactic Body Radiotherapy1 trial

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Recruiting·—·Phase 2·NCT04830267·39 enrolled

Adjuvant Treatment1 trial

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.

Unknown status·SShanghai Chest Hospital·Phase 2·NCT05005468·61 enrolled

Adjuvant Chemotherapy1 trial

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

Recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT05825443·57 enrolled

Locally Advanced Head and Neck Cancer1 trial

A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

Unknown status·WWest China Hospital·Phase 2·NCT04405154·32 enrolled

Neuroendocrine Carcinoma1 trial

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Unknown status·HHuazhong University of Science and Technology·Phase 2·NCT05142865·30 enrolled

Lung Adenocarcinoma1 trial

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Unknown status·HHunan Cancer Hospital·Phase 2·NCT04459078·63 enrolled

Chemotherapy1 trial

Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05097248·52 enrolled

Advanced or Metastatic NSCLC1 trial

A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC

Unknown status·SSun Yat-sen University·Phase 2·NCT04167774·62 enrolled

Liver Transplant1 trial

IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation

Unknown status·RRenJi Hospital·N/A·NCT05339581·78 enrolled

ALK-positive Advanced NSCLC1 trial

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT04425135·59 enrolled

Neoadjuvant Immunotherapy1 trial

Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer

Recruiting·PPeking Union Medical College Hospital·N/A·NCT06215677·18 enrolled

Gastrointestinal1 trial

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Unknown status·HHarbin Medical University·Phase 2·NCT05225844·150 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04539600·23 enrolled

Ovarian Cancer1 trial

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Unknown status·QQianfoshan Hospital·N/A·NCT04507750·40 enrolled

Cholangiocarcinoma1 trial

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

Recruiting·FFudan University·Phase 2·NCT07105748·45 enrolled

Advanced Solid Tumor1 trial

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04346381·233 enrolled

Second-line Treatment1 trial

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Unknown status·FFeng Wang·Phase 3·NCT05049681·234 enrolled

Advanced1 trial

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Recruiting·SSun Yat-sen University·N/A·NCT06061276·40 enrolled

Glioblastoma1 trial

Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04583020·42 enrolled

PD-1 Inhibitor1 trial

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT05772273·43 enrolled

Lung Cancer1 trial

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

Unknown status·SShandong Provincial Hospital·Phase 2·NCT04102982·200 enrolled

Pancreatic Adenocarcinoma1 trial

Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma

Unknown status·SSun Yat-sen University··NCT04365049·100 enrolled

Neoadjuvant Therapy1 trial

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

Recruiting·HHuazhong University of Science and Technology·Phase 2·NCT06516445·33 enrolled

Immunotherapy1 trial

A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC

Recruiting·GGrandPharma (China) Co., Ltd.·Phase 2·NCT07334483·120 enrolled

Immunochemotherapy1 trial

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Recruiting·TTongji Hospital·Phase 2·NCT06288360·40 enrolled

Chemoradiotherapy1 trial

Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

Unknown status·SSun Yat-sen University·Phase 2·NCT05114707·57 enrolled

PTCL1 trial

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown status·RRuijin Hospital·Phase 1/2·NCT05559008·116 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Active, not recruiting·FFudan University·Phase 1/2·NCT04706598·25 enrolled

Osteosarcoma1 trial

Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma

Unknown status·PPeking University People's Hospital·Phase 2·NCT04351308·60 enrolled

Gastric Adenocarcinoma1 trial

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT04948125·20 enrolled

First Line Therapy1 trial

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

Unknown status·PPeking Union Medical College Hospital·Phase 1/2·NCT04443309·53 enrolled

Central Nervous System Lymphoma1 trial

Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Recruiting·—·Phase 2·NCT04070040·21 enrolled

Esophageal Squamous Cell Cancer1 trial

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·N/A·NCT04654403·337 enrolled

Refractory Solid Tumors1 trial

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03871855·8 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT05490485·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 225 trial records for Camrelizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Camrelizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Camrelizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death Protein 1 Antagonist[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

Related News